Vaccination is one of the most effective and cost-efficient methods for protecting people with multiple sclerosis (MS) from infections. However, use of vaccines has often been problematic because of misguided concerns that they may exacerbate the disease and/or that some disease-modifying therapies may influence the immune response to immunisations and/or their safety. People with MS risk higher morbidity and mortality from vaccine-preventable infections. It is, therefore, important to address any patient’s reluctance to accept vaccination and to provide clear guidance for clinicians on which vaccinations to consider proactively. We have reviewed the current literature and provide recommendations regarding vaccines in adults with MS, including specific advice regarding vaccination safety in patients receiving—or going to receive—disease-modifying therapies, vaccination during pregnancy, pretravel counselling and patient education.
- Multiple Sclerosis
- Trigeminal Neuralgia
- Infectious Diseases
- Magnetic Stimulation
- Stiff Man Syndrome
- Lambert-Eaton Syndrome
This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Twitter G Giovannoni @gavingiovannoni.
Contributors SR and GG conceived the review. SR, NS and GG wrote the first draft of the manuscript. All the authors participated in the critical revision of the manuscript.
Competing interests None declared.
Patient consent for publication Not required.
Ethical approval information Not applicable.
Data sharing statement Not applicable.
Provenance and peer review Not commissioned; externally peer reviewed by Neil Scolding, Bristol, UK.
Read the full text or download the PDF:
Other content recommended for you
- Principles of immunisation in children with solid organ transplant
- Multiple sclerosis and the risk of infection: Association of British Neurologists consensus guideline
- 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases
- EULAR/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021
- Vaccination and multiple sclerosis in the era of the COVID-19 pandemic
- EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases
- Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases
- Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations
- Non-specific effects of measles, mumps, and rubella (MMR) vaccination in high income setting: population based cohort study in the Netherlands
- MMR vaccine - how effective and how safe?